Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Gopal

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
The Journal of Urology|June 15, 2014
Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsyMichael A Liss, Stephen A Taylor, Deepak Batura, et al.
Journal of the American Academy of Dermatology|July 18, 2015
Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled studySunil Dogra, Krupashankar D S, Leelavathy Budamakuntla, et al.
Journal of the American Academy of Dermatology|April 8, 2014
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III studyD S Krupashankar, Sunil Dogra, Mahendra Kura, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
The Journal of Urology|June 15, 2014
Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsyMichael A Liss, Stephen A Taylor, Deepak Batura, et al.
Journal of the American Academy of Dermatology|July 18, 2015
Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled studySunil Dogra, Krupashankar D S, Leelavathy Budamakuntla, et al.
Journal of the American Academy of Dermatology|April 8, 2014
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III studyD S Krupashankar, Sunil Dogra, Mahendra Kura, et al.
Pageof 8